MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.78
+1.51
+2.95%
After Hours: 52.78 0 0.00% 16:29 03/05 EST
OPEN
51.66
PREV CLOSE
51.27
HIGH
52.80
LOW
49.68
VOLUME
918.68K
TURNOVER
--
52 WEEK HIGH
64.37
52 WEEK LOW
39.32
MARKET CAP
7.43B
P/E (TTM)
-16.3552
1D
5D
1M
3M
1Y
5Y
Oligonucleotide Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 04, 2021 (Market Insight Reports) -- The report for Oligonucleotide Therapeutics offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 3d ago
RNA-interference (RNAi) Market Segmentation and Analysis by Recent Trends, consumption by Regional data, Development, Investigation, Growth by to 2026
The Express Wire · 5d ago
Spinal Muscular Atrophy (SMA) Treatment Market Size, Share, Growth, Research and Forecast 2019-2025
Mar 02, 2021 (Market Insight Reports) -- The global spinal muscular atrophy (SMA) treatment market is projected to exhibit considerable growth during the...
Market Insight Reports · 6d ago
Retinitis Pigmentosa Treatment Market 2021 Industry Share, Top Manufacturers Analysis, Size, Demand, Growth Strategy, Trends, Supply, Revenue and 2027 Forecast Research
Mar 01, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Retinitis Pigmentosa Treatment...
The Express Wire · 6d ago
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
CARLSBAD, Calif., March 1, 2021 /PRNewswire via COMTEX/ -- CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today...
PR Newswire - PRF · 6d ago
--Analyst Actions: Barclays Upgrades Ionis Pharmaceuticals to Equal-Weight From Underweight, Adjusts Price Target to $52 From $50
MT Newswires · 6d ago
GSK3228836- Emerging Drug Insight and Market Forecast - 2030
Feb 26, 2021 (Heraldkeepers) -- "GSK3228836- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an...
Heraldkeepers · 02/26 17:14
--Analyst Actions: UBS Adjusts Ionis Pharmaceuticals' Price Target to $33 From $34, Maintains Sell Rating
MT Newswires · 02/26 10:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IONS. Analyze the recent business situations of Isis Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IONS stock price target is 65.47 with a high estimate of 120.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 615
Institutional Holdings: 131.73M
% Owned: 93.52%
Shares Outstanding: 140.86M
TypeInstitutionsShares
Increased
122
12.07M
New
106
822.49K
Decreased
112
11.65M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Executive Director
Stanley Crooke
Chief Executive Officer/Director
Brett Monia
Chief Financial Officer/Senior Vice President - Finance
Elizabeth Hougen
Executive Vice President
Eugene Schneider
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Patrick O'Neil
Senior Vice President
Richard Geary
Senior Vice President
Eric Swayze
Chief Scientific Officer
C. Frank Bennett
Other
Onaiza Cadoret-Manier
Director
Joan Herman
Director
B. Lynne Parshall
Independent Director
Spencer Berthelsen
Independent Director
Breaux Castleman
Independent Director
Michael Hayden
Independent Director
Joseph Klein
Independent Director
Joseph Loscalzo
Independent Director
Frederick Muto
Independent Director
Peter Reikes
Independent Director
Joseph Wender
No Data
  • All
  • Financials
  • Insiders
More
About IONS
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Webull offers kinds of Ionis Pharmaceuticals Inc stock information, including NASDAQ:IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.